Omega Fund Management LLC held its stake in shares of Juno Therapeutics Inc (NASDAQ:JUNO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,229,512 shares of the biopharmaceutical company’s stock at the end of the first quarter. Juno Therapeutics comprises 17.7% of Omega Fund Management LLC’s portfolio, making the stock its 2nd largest position. Omega Fund Management LLC owned approximately 1.19% of Juno Therapeutics worth $27,283,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. State Board of Administration of Florida Retirement System boosted its stake in shares of Juno Therapeutics by 11.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 67,000 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 7,137 shares in the last quarter. First Washington CORP boosted its stake in shares of Juno Therapeutics by 64.5% in the third quarter. First Washington CORP now owns 65,320 shares of the biopharmaceutical company’s stock valued at $1,960,000 after buying an additional 25,620 shares in the last quarter. Guggenheim Capital LLC boosted its stake in shares of Juno Therapeutics by 11.9% in the fourth quarter. Guggenheim Capital LLC now owns 146,738 shares of the biopharmaceutical company’s stock valued at $2,766,000 after buying an additional 15,588 shares in the last quarter. Norges Bank purchased a new stake in shares of Juno Therapeutics during the fourth quarter valued at $13,993,000. Finally, State Street Corp boosted its stake in shares of Juno Therapeutics by 16.3% in the fourth quarter. State Street Corp now owns 3,415,744 shares of the biopharmaceutical company’s stock valued at $64,380,000 after buying an additional 478,044 shares in the last quarter. Institutional investors and hedge funds own 61.80% of the company’s stock.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded down 5.44% during midday trading on Friday, hitting $23.64. The company had a trading volume of 1,283,017 shares. Juno Therapeutics Inc has a 12 month low of $17.52 and a 12 month high of $49.72. The company has a 50-day moving average of $24.16 and a 200 day moving average of $22.56. The firm’s market capitalization is $2.46 billion.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.01. The company had revenue of $19.30 million during the quarter, compared to analysts’ expectations of $16 million. Juno Therapeutics had a negative net margin of 445.86% and a negative return on equity of 22.10%. The company’s revenue for the quarter was up 96.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.78) earnings per share. On average, analysts expect that Juno Therapeutics Inc will post ($3.04) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/05/20/omega-fund-management-llc-holds-position-in-juno-therapeutics-inc-juno.html.
Several equities research analysts have weighed in on JUNO shares. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Tuesday, March 7th. Cowen and Company reiterated a “buy” rating and issued a $36.00 target price (down from $41.00) on shares of Juno Therapeutics in a report on Thursday, March 30th. Vetr upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $25.42 target price for the company in a report on Tuesday, March 21st. Wedbush started coverage on Juno Therapeutics in a report on Wednesday, February 1st. They issued a “neutral” rating and a $24.00 target price for the company. Finally, Wells Fargo & Co started coverage on Juno Therapeutics in a report on Wednesday, February 22nd. They issued an “outperform” rating for the company. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $32.56.
In related news, Director Anthony B. Evnin bought 8,000 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The stock was purchased at an average cost of $22.11 per share, for a total transaction of $176,880.00. Following the completion of the acquisition, the director now owns 56,990 shares in the company, valued at approximately $1,260,048.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 15.26% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.